Related Experiment Video

Updated: Jul 11, 2026

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats
07:31

A Model of Cardiac Remodeling Through Constriction of the Abdominal Aorta in Rats

Published on: December 2, 2016

Candesartan: from left ventricular hypertrophy to heart failure, a global approach

Vivencio Barrios1, Carlos Escobar, Alberto Calderon

  • 1Department of Cardiology, Hospital Ramón y Cajal, Ctra. Colmenar km 9.100, 28034 Madrid, Spain. vbarriosa@meditex.es

Expert Review of Cardiovascular Therapy
|September 18, 2007
PubMed

Insights

Candesartan effectively treats cardiovascular disease stages, including hypertension and heart failure. The Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity program showed it reduces cardiovascular deaths and hospitalizations in heart failure patients.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Cardiovascular disease progresses from risk factors to severe pathology.
  • Overactivation of the renin-angiotensin-aldosterone system contributes to hypertension and heart failure.
  • Early intervention is crucial for managing cardiovascular disease progression.

Purpose of the Study:

  • To review data supporting candesartan's use in cardiovascular medicine.
  • To focus on candesartan's efficacy in left ventricular hypertrophy and heart failure.
  • To highlight findings from the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program.

Main Methods:

  • Review of clinical data on candesartan.
  • Analysis of studies focusing on left ventricular hypertrophy and heart failure.
  • Emphasis on the CHARM program's outcomes.

Main Results:

  • Candesartan is an effective and well-tolerated therapy across cardiovascular disease stages.
  • The CHARM program demonstrated candesartan reduces cardiovascular deaths in chronic heart failure.
  • Candesartan use led to fewer hospitalizations for chronic heart failure.

Conclusions:

  • Candesartan is a valuable treatment option for various cardiovascular conditions.
  • Early and late-stage cardiovascular disease management benefits from candesartan.
  • Candesartan significantly improves outcomes for patients with chronic heart failure.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...